NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.
- Two years following a fecal transplant treatment, test subjects retained improvements in autism symptoms and gut he… https://t.co/fbm7fV32NY6 hours ago
- CEO Elizabeth Donley presented findings from CAMP at the National @TACAfoundation Autism Conference – East Coast. D… https://t.co/p54MQvZlAcyesterday
- Is it time to rethink #AutismAwarenessMonth? https://t.co/tKunyTlAyS #Autism #AutismAcceptanceyesterday